Compare Fubotv Inc (FUBO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Incyte Corporation — how do they compare? Fubotv Inc trades at $10.51 (market cap $302.39M), while Incyte Corporation trades at $116.44 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 76× Fubotv Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| FUBO | INCY | |
|---|---|---|
Market Cap | $302.39M | $22.99B |
Sector | Technology | Health |
52-Week High | $54.72 | $118.52 |
52-Week Low | $8.09 | $67.38 |
Enterprise Value | $472.81M | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.54, down 2.95% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $172.25 million in 2024, but revenue grew to $1.62 billion, and profitability improved significantly in 2025 with a net income margin of 7.61%. Valuation ratios appear low, with a P/E of 2.67 and P/S of 0.21. Recent news highlights the appointment of a new CEO from Disney, sparking investor optimism about future growth.
The outlook is mixed; low valuations and a path to profitability present opportunity, but persistent cash flow challenges and high debt levels pose significant risks. Analyst consensus is a Buy with a $16.25 price target, suggesting substantial upside if the new leadership can execute on growth and monetization strategies effectively.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
